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The immune system has long been thought to be involved in the pathophysiology of complex regional pain syndrome (CRPS).
However, not much is known about the role of the immune system and speciﬁcally T-cells in the onset and maintenance of this
disease. In this study, we aimed to evaluate T-cell activity in CRPS by comparing blood soluble interleukin-2 receptor (sIL-2R)
levels between CRPS patients and healthy controls. CRPS patients had statistically signiﬁcant elevated levels of sIL-2R as
compared to healthy controls (median sIL-2R levels: 4151 pg/ml (Q3−Q1= 5731 pg/ml− 3546 pg/ml) versus 1907 pg/ml
(Q3−Q1: 2206 pg/ml− 1374 pg/ml), p < 0 001, resp.). Furthermore, sIL-2R level seems to be a good discriminator between
CRPS patients and healthy controls with a high sensitivity (90%) and speciﬁcity (89.5%). Our ﬁnding indicates increased
T-cell activity in patients with CRPS. This ﬁnding is of considerable relevance as it could point towards a T-cell-mediated
inﬂammatory process in this disease. This could pave the way for new anti-inﬂammatory therapies in the treatment of
CRPS. Furthermore, sIL-2R could be a promising new marker for determining inﬂammatory disease activity in CRPS.
1. Introduction
Complex regional pain syndrome (CRPS) is a clinical disor-
der characterized by severe pain in an aﬀected extremity that
is accompanied by sensory, motor, vasomotor, and sudomo-
tor disturbances [1]. CRPS is often preceded by an injury to
an extremity such as a fracture or surgery [2].
The exact pathophysiology of CRPS is still unknown.
CRPS is considered to be a multimechanism disease [3].
The following mechanisms have been proposed to play a role
in CRPS: inﬂammation, central and peripheral sensitization,
altered sympathetic nervous system function, endothelial
dysfunction, brain plasticity, and psychological factors [3–5].
Inﬂammation as an underlying pathogenic mechanism
for CRPS has long been a topic of debate, as systemic markers
of inﬂammation such as erythrocyte sedimentation rate
(ESR), c-reactive protein (CRP), and white blood cell
(WBC) count are usually not elevated in CRPS patients
[6–8]. However, classic signs of inﬂammation such as
pain, swelling, and redness are often present during phys-
ical examination, especially in the initial stages of the
disease, suggesting that inﬂammation does contribute to
CRPS [9, 10]. The latter is supported by research ﬁndings
that demonstrated increased levels of the proinﬂammatory
cytokines’ tumor necrosis factor alpha (TNF-α) and interleu-
kin- (IL-) 6 in skin blister ﬂuid of the aﬀected limbs versus
the unaﬀected limbs of CRPS patients [11, 12]. Further,
recent studies have conﬁrmed evidence of systemic inﬂam-
mation in the venous blood of CRPS patients [7, 13].
An interesting theory on inﬂammation in CRPS was put
forward by Goebel and Blaes suggesting that CRPS is a novel
kind of antibody-mediated autoimmune disease [14].
To expand on this theory, our research group previously
analyzed the presence of antinuclear antibodies (ANA) and
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antineuronal antibodies in CRPS patients and demonstrated
increased ANA positivity in CRPS patients as compared to
healthy controls (33% versus 4%, resp., p < 0 001) [15]. The
frequency of positivity for antineuronal antibodies did not
diﬀer between the groups [15]. Considering our ﬁndings
and those of Goebel et al., we could not deﬁne CRPS as an
antibody-mediated autoimmune disease in accordance with
Witebsky’s criteria for autoimmune diseases [14–19]. There-
fore, we shifted our focus to exploring the role of T-cells in
the inﬂammation seen in CRPS.
Hitherto, very few studies have been conducted on the
role of T-cells in CRPS [6, 20, 21]. These studies were
conducted using diﬀerent methodologies and had diﬀerent
outcome parameters, making comparison between the stud-
ies and thus establishment of a ﬁrm conclusion diﬃcult.
Furthermore, some data presented in these studies are
contradictory; for example, while one study showed no
diﬀerence in blood lymphocyte populations (i.e., (cytotoxic)
CD8+ T-cells, CD4+ T-cells, B-cells, and natural killer (NK)
cells) between CRPS patients and healthy controls, another
study found that CRPS was associated with a signiﬁcant
reduction in the number of CD8+ T-cells [6, 20].
Another approach to study T-cell involvement in CRPS is
to analyze whether there are indications of increased T-cell
activity in CRPS, for instance by the measurement of soluble
interleukin-2 receptor levels in the peripheral blood.
Interleukin-2 (IL-2) is a cytokine crucially important in
regulating activation, proliferation, and survival of diﬀerent
T-cell subsets [22, 23]. This eﬀect of IL-2 is mediated through
the IL-2 receptor which consists of the common γ-chain
(CD132), a β-chain (CD122), and an α-chain (CD25) [22,
24]. CD25 is strongly expressed on activated T-cells which
also secrete this molecule as a soluble variant (referred to as
soluble IL-2 receptor; sIL-2R) from the cell membrane into
the circulation [22, 25, 26].
Peripheral blood levels of sIL-2R have been found to
reﬂect the level of T-cell activation, and elevated sIL-2R levels
correlate with disease activity in for instance rheumatoid
arthritis and sarcoidosis, diseases in which T-cell activation
is centrally involved [22, 24, 25, 27–30].
Finding increased levels of sIL-2R in CRPS could be
indicative of a T-cell-mediated inﬂammatory process in this
disease. This ﬁnding could contribute to a better understand-
ing of the underlying inﬂammatory pathophysiological
mechanism in CRPS. This could further lead to the develop-
ment and application of (new) therapies in the treatment of
CRPS patients with (T-cell-mediated) inﬂammation as an
underlying mechanism of their disease.
Therefore, the aim of this study was to evaluate T-cell
activity in CRPS by examining the levels of sIL-2R in a group
of CRPS patients and comparing these to sIL-2R levels in a
group of healthy controls.
2. Materials and Methods
2.1. Ethical Approval. This study was approved by the
Medical Ethics Committee of Erasmus MC University
Medical Center Rotterdam (MEC-2016-172).
2.2. Patients and Controls. Patients who visited the Center for
Pain Medicine at Erasmus MC University Medical Center
Rotterdam between 2001 and 2007 and fulﬁlled the
Harden-Bruehl diagnostic criteria for CRPS were invited to
participate in various ongoing studies [31].
In the context of these studies, venous blood samples
were drawn from patients and plasma was stored in a refrig-
erator at −80 degrees Celsius for use in future research with
permission from the patients.
For this study, we examined the levels of sIL-2R in the
plasma of 80 adult patients with CRPS type I and compared
this to sIL-2R levels measured in 76 anonymous healthy
blood bank donors who also had given permission to use
their blood for future research purposes.
2.3. sIL-2R Analysis. Venous blood samples were centrifuged
at 3000 rpm immediately after collection for a duration of 10
minutes. Plasma was stored at −80 degrees Celsius and
thawed to room temperature for sIL-2R analysis.
sIL-2R plasma levels were quantiﬁed using an enzyme-
linked immunosorbent assay (Human sCD25/sIL-2R ELISA
kit, Besancon, Cedex, France) in accordance with the manu-
facturer’s instructions. sIL-2R levels are expressed in pico-
grams per milliliter (pg/ml), and levels > 2500 pg/ml are
considered elevated.
2.4. Statistical Analysis. Descriptive statistics were used to
determine the frequencies of the demographic variables and
plasma sIL-2R levels and to describe the measures of central
tendency and of variability. The Shapiro-Wilk test was used
to test the distribution of these variables for normality.
Results are reported in medians and interquartile ranges
(Q3−Q1) if the distribution is skewed and otherwise in
means and standard deviations (SD).
Diﬀerences in sIL-2R levels between the CRPS patients
and the healthy blood bank donors were analyzed using the
independent-samples Mann–Whitney U test (two-sided).
A possible association between sIL-2R levels of the CRPS
patients, their age, gender, and duration of the CRPS was also
explored. An association with gender was evaluated using the
independent-samples Mann–Whitney U test (two-sided).
With regard to the age of patients and the duration of CRPS,
Spearman’s rank correlation was used (two-sided).
A binary logistic regression was used to evaluate the con-
tribution of the level of sIL-2R to the prediction of the group
(CRPS patients versus healthy controls). A receiver operating
characteristic (ROC) curve was computed. The sensitivity,
speciﬁcity, positive predictive value (PPV), and negative pre-
dictive value (NPV) of sIL-2R were calculated.
The alpha level for statistical signiﬁcance was set at 0.05.
Analyses were performed using IBM SPSS Statistics 21.
3. Results
Plasma was available from 80 CRPS patients. The character-
istics of our CRPS patient group are depicted in Table 1.
The median sIL-2R level of the CRPS group was statisti-
cally signiﬁcantly higher compared to the median sIL-2R
level of the control group. The median of the CRPS patients
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was 4151pg/ml (Q3−Q1=5731 pg/ml− 3546pg/ml) and
that of the control subjects was 1907 pg/ml (Q3−Q1:
2206 pg/ml− 1374 pg/ml), p < 0 001 (see Figure 1).
Plasma levels of sIL-2R between male and female CRPS
patients were also compared. The sIL-2R plasma levels in
men were statistically signiﬁcantly higher than in women
(men 5602 pg/ml, Q3−Q1=5829 pg/ml− 3921 pg/ml versus
women 4016 pg/ml, Q3−Q1=4951pg/ml− 3286 pg/ml,
p=0.03) (see Figure 2).
No association was found in the CRPS patient
group between sIL-2R levels and the duration of dis-
ease (rs = − 0 18, p = 0 10) nor between sIL-2R levels and
the age of patients (rs = 0 12, p = 0 28).
The level of sIL-2R showed a favorable discrimination
between CRPS patients and healthy controls. The sensitivity
was observed to be 90%, speciﬁcity 89.5%, PPV 90%, and
NPV 89.5%, using a cut-oﬀ value of 0.5, which corresponds
with an sIL-2R level of 3730 pg/ml (see Table 2, Figure 3).
4. Discussion
This study was conducted to explore whether T-cell activa-
tion is involved in the pathophysiology of CRPS. To this
end, venous blood levels of sIL-2R in CRPS patients were
compared to those of healthy controls. Our data clearly dem-
onstrate that plasma sIL-2R levels are signiﬁcantly elevated in
CRPS patients. This ﬁnding is of considerable relevance as it
indicates increased T-cell activity in CRPS and therefore
could point towards an underlying T-cell-mediated inﬂam-
matory process in this disease.
There is one earlier study which has shown signiﬁ-
cantly elevated plasma levels of sIL-2R in CRPS patients
[32]. However, the aim of this study was to conduct an
explorative analysis of various plasma analytes in CRPS
patients and to subsequently derive diﬀerent CRPS clusters
based on their ﬁndings [32]. The authors did not relate
this ﬁnding of higher plasma levels of sIL-2R to T-cell
activity [32]. This seems to be more an ancillary ﬁnding,
but it strongly supports our results.
In our study, we observed higher sIL-2R plasma levels in
men with CRPS as compared to those in women with CRPS.
We could not compare the gender distribution of sIL-2R
levels in our CRPS group to the group of healthy controls
as this was an anonymous group without any available demo-
graphic data. However, other studies do not report elevated
blood sIL-2R levels in healthy men compared to healthy
women [22, 33–35].
Our ﬁnding of a signiﬁcant diﬀerence in sIL-2R levels
between CRPS men and women conﬂicts with the ﬁnding
of the previously mentioned explorative study [32]. This
study found no diﬀerences in sIL-2R levels between men
and women with CRPS [32]. One explanation for the con-
tradictory results could be the possibility of higher disease
severity in our group of male CRPS patients, as sIL-2R
levels have been shown to correlate with disease severity
in other disease entities [28].
We found no association between sIL-2R levels and
age in the CRPS group. Studies in healthy individuals have
shown sIL-2R levels to vary with age [22]. Children (age
1–14 years) and the elderly (age 67–99 years) have been
shown to have higher sIL-2R levels as compared to
(young) adults (age 22–67 years) [22, 33, 35]. This could
explain why no association was found between sIL-2R
Table 1: Characteristics of the CRPS patients.
Characteristics n = 80
Women (n, %) 67 (83.8)
Age in years (mean, SD) 44.4 (12.25)
CRPS duration in months (median, Q3−Q1) 11 (36− 5)
Upper limb (n, %) 46 (57.5)
Warm/cold/unknown CRPS
Warm CRPS (n, %) 30 (37.5)
Cold CRPS (n, %) 44 (55.0)
Unknown (n, %) 6 (7.5)
Precipitating injury
Trauma (n, %) 51 (63.8)
Surgery (n, %) 21 (26.3)
Spontaneous onset (n, %) 6 (7.5)
Missing (n, %) 2 (2.5)
Control CRPS
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Figure 1: Boxplot of the sIL-2R level by the experimental group.
∗Healthy controls with sIL-2R levels that are more than three
times the IQ-range.
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Figure 2: Boxplot of the sIL-2R level by gender in CRPS patients.
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levels and age as our CRPS patient sample consisted
mainly of (young) adults with a mean age of 44.4 years
(SD 12.25).
No association was found between sIL-2R levels and
duration of disease, suggesting immune system activation
throughout the entire disease course in a subgroup of CRPS
patients.
Finally, our ﬁndings show sIL-2R level to be a good dis-
criminator between CRPS patients and healthy controls. This
ﬁnding could lead not only to the use of sIL-2R as a marker of
inﬂammatory disease activity in CRPS but also to the use of
sIL-2R during the diagnostic work-up of this disease. As
per our knowledge, no study has yet been performed on this
subject. Consequently, further studies are required to validate
sIL-2R as a marker of inﬂammatory disease activity in
CRPS and to establish a validated diagnostic cut-oﬀ value
to diﬀerentiate CRPS from other chronic pain diseases
(e.g., ﬁbromyalgia) and autoimmune and autoinﬂamma-
tory disorders (e.g., rheumatoid arthritis).
While our ﬁndings indicate increased T-cell activity in
CRPS, it is still unclear what subset of T-cells is being acti-
vated as sIL-2R is T-cell subset nonspeciﬁc and is thus
measured during activation of diﬀerent T-cell subsets [22].
Previous studies have tried characterizing changes in
lymphocyte subsets in CRPS [20, 21]. In 2007, Kaufmann
et al. investigated the inﬂuence of pain and stress on
lymphocyte numbers, lymphocyte subpopulations, and T-
helper 1/T-helper 2 (Th1/Th2) ratio in CRPS patients,
ﬁbromyalgia patients, and healthy controls [20]. They
found a signiﬁcant reduction of CD8+ T-lymphocytes in
CRPS patients as compared to healthy controls [20].
In 2015, Osborne et al. studied skin immune cell pop-
ulations in long-standing CRPS and found no signiﬁcant
diﬀerences in overall immune cell inﬁltrates between CRPS
aﬀected and unaﬀected limbs [21].
As stated previously, while our ﬁndings indicate
increased T-cell activity in CRPS, we cannot specify which
subset(s) of T-cells are active, making it diﬃcult to relate
our ﬁndings to the ﬁndings from the studies mentioned
above [20, 21]. Moreover, both studies used diﬀerent meth-
odologies to study the involvement of T-cells (i.e., skin punch
biopsies in the study by Osborne et al. and venous blood
samples in the study by Kaufmann et al.) [20, 21]. Further-
more, Osborne et al. compared the unaﬀected and aﬀected
extremities in CRPS patients (side to side comparison) while
Kaufmann et al. looked at diﬀerences between CRPS patients,
ﬁbromyalgia patients, and healthy controls [20, 21]. As a
consequence, comparison of our results to those of
Kaufmann et al. or to those of Osborne et al. is rather
meaningless [20, 21].
Further, the internal and external validity of this current
study should be evaluated taking into account the potential
incomparability of the experimental groups in terms of age,
gender, past history, and medication as demographic data
and medical history were unavailable for the control group.
Finally, our study consists of a cross-sectional measure-
ment of sIL-2R levels in CRPS patients and healthy blood
bank donors. It would be interesting to prospectively study
sIL-2R levels during the course of this disease. This could
increase our understanding on the role of T-cell activity in
the onset and maintenance of CRPS.
Based on the ﬁndings of this study, we propose a role of
T-cell-mediated inﬂammation as an underlying mechanism
in the pathophysiology of CRPS.
Our results are of considerable relevance as the involve-
ment of T-cells in CRPS could lead to a better understanding
of the rather complex pathophysiology of this disease. The
ﬁndings of this study and the results of possible future
research might lead to new therapeutic targets in the treat-
ment of CRPS patients with (T-cell-mediated) inﬂammation
as an underlying mechanism of disease, thereby paving the
way for new anti-inﬂammatory and/or immunomodulating
therapies in the management of CRPS.
5. Conclusion
The median sIL-2R level of CRPS patients was found to be
signiﬁcantly increased as compared to that of a group of
healthy blood bank donors. This result indicates increased
T-cell activity in CRPS.
This ﬁnding could point towards a T-cell-mediated
inﬂammatory process in CRPS, which could pave the way
for new anti-inﬂammatory therapies in the treatment of
CRPS patients with (T-cell-mediated) inﬂammation as their
underlying mechanism of disease. However, the precise role
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Figure 3: Receiver operating characteristic curve of sIL-2R as a
predictor of group (CRPS patients versus healthy controls). Area
under the curve 0.958 (SE 0.016), p < 0 001.
Table 2: Results of the binary logistic regression analysis.
95% CI for odds ratio
B (SE) [p value] Lower Odds ratio Upper
Included
Constant −6.96 (1.11) [<0.001]
sIL-2R 0.002 (<0.001) [<0.001] 1.002 1.002 1.003
R2 = .57 (Cox & Schnell), .76 (Nagelkerke), model χ2(1) = 130.33, p < 0 001.
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of T-cells in the pathophysiology of CRPS has yet to be
unraveled.
Furthermore, sIL-2R level seems to be a good discrimina-
tor between CRPS patients and healthy controls. CRPS is still
a clinical diagnosis. Until now, no diagnostic test exists for
monitoring inﬂammatory disease activity in CRPS. Based
on our ﬁndings, sIL-2R could be a promising new marker
to determine inﬂammatory disease activity in CRPS. How-
ever, this must be validated in future research.
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